Does headache at week ten of retatrutide usually resolve without a dose change?

Accepted answer

Week 10 is day 70: on a four-week ladder that is week 2 of dose step 3, and — at the seven-day half-life this class runs on — 10 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 70 is 5 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 2 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Headache in a sustained deficit is more often fluid or intake than receptor pharmacology, and both are cheaper to exclude than to argue about. Dose decisions are made under supervision, and nothing here is medical advice.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Label titration ladders, structure only

Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.

The underlying point is that liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Stepping back is a normal adjustment, not a failure.